Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

P-023

Supelco

Phentermine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C10H15N
Número CAS:
122-09-8
Peso molecular:
149.23
Número MDL:
MFCD00059195
Código UNSPSC:
41116107
ID de substância PubChem:
329820023
NACRES:
NA.24

grau

certified reference material

Nível de qualidade

300

Formulário

liquid

Características

Snap-N-Spike®/Snap-N-Shoot®

embalagem

ampule of 1 mL

fabricante/nome comercial

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IIB (Portugal)

concentração

1.0 mg/mL in methanol

técnica(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

aplicação(ões)

clinical testing

Formato

single component solution

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

NC(C)(C)CC1=CC=CC=C1

InChI

1S/C10H15N/c1-10(2,11)8-9-6-4-3-5-7-9/h3-7H,8,11H2,1-2H3

chave InChI

DHHVAGZRUROJKS-UHFFFAOYSA-N

Categorias relacionadas

Descrição geral

A Snap-N-Spike® reference solution applicable for use in clinical toxicology or urine drug testing by LC-MS/MS or GC/MS. Phentermine, a phenethylamine analog, is a stimulant and an appetite suppressant. This drug is a constituent of the withdrawn anti-obesity medication fen-phen.

Aplicação

  • Phentermine solution for weight loss research: Phentermine is extensively studied as an appetite suppressant in obesity treatment. Its effectiveness in weight loss regimens is often analyzed through pharmaceutical research, where the solution form facilitates precise dosing and control in clinical trials, enhancing the understanding of its pharmacodynamics and therapeutic potential (Ni et al., 2015).

Informações legais

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Palavra indicadora

Danger

Classificações de perigo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Órgãos-alvo

Eyes

Código de classe de armazenamento

3 - Flammable liquids

Classe de risco de água (WGK)

WGK 1

Ponto de fulgor (°F)

49.5 °F - closed cup

Ponto de fulgor (°C)

9.7 °C - closed cup

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Lamentamos, não temos COA para este produto disponíveis online no momento.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Fiona Cameron et al.
Drugs, 72(15), 2033-2042 (2012-10-09)
Vivus' proprietary oral capsule containing phentermine and extended-release (ER) topiramate has been approved in the US for the treatment of obesity. Phentermine is an appetite suppressant, while topiramate is an anti-epileptic medication. The once-daily formulation, known as Qsymia™, is designed
Prescrire international, 22(136), 61-64 (2013-04-18)
The cornerstones of treatment for obesity, and even more so for simple overweight, are dietary measures and physical exercise. There are no drugs with a favourable harm-benefit balance in this setting. A fixed-dose combination of topiramate, an antiepileptic drug, and
Two new drugs approved for obesity.
Annette M Johnson
South Dakota medicine : the journal of the South Dakota State Medical Association, 65(9), 356-357 (2012-10-17)
Eva Manakova et al.
Neuro endocrinology letters, 33 Suppl 3, 179-182 (2013-01-29)
Both, obesity as well as anorexia may be associated with infertility and other complications of pregnancy. Weight loss during pregnancy is therefore considered a risk factor. Weight loss and appetite suppressant are contraindicated during pregnancy, but the unintended exposure is
New medications for weight loss.
Melissa Murfin
JAAPA : official journal of the American Academy of Physician Assistants, 25(12), 59-60 (2013-04-23)
Exibir todos os documentos relacionados

Protocolos

US EPA Method 8270 (Appendix IX): GC Analysis of Semivolatiles on Equity®-5 (30 m x 0.25 mm I.D., 0.50 μm)

US EPA Method 8270 (Appendix IX): GC Analysis of Semivolatiles on Equity®-5 (30 m x 0.25 mm I.D., 0.50 μm)

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica